Marksans Pharma shareholders approved a final dividend of ₹0.90 per equity share and reappointed key board members at its 34th annual general meeting held on August 27, 2026.

The meeting, conducted via video conferencing, saw all resolutions pass with requisite majorities. Shareholders also adopted the audited standalone and consolidated financial statements for FY26.

Voting Participation

A total of 2,50,569 shareholders were on record as of the August 20, 2026 cut-off date. Voting occurred through remote e-voting from August 24 to August 26, 2026, and during the AGM itself.

Promoters voted in full on all resolutions. Institutional participation remained high at over 80%, while non-institutional public participation stood at approximately 21.6%.

Resolution Outcomes

All four resolutions were passed. The dividend declaration and adoption of accounts faced negligible opposition. However, the reappointment of Dr. Sunny Sharma saw notable dissent from institutional investors.

Key Resolutions Passed

• Adoption of Financials: Approved with 100% support on polled votes. Only 7,427 votes were cast against.
• Final Dividend: A ₹0.90 (90%) dividend per share of Re. 1 face value was approved. It received 99.81% support, with 559,059 votes against.
• Director Reappointment: Dr. Sunny Sharma was reappointed upon retirement by rotation. The resolution passed with 98.81% support.
• WTD Appointment: Mrs. Sandra Saldanha was reappointed as Whole-time Director for three years starting September 25, 2026. This special resolution passed with 99.61% support.

What the Numbers Show

Institutional investors demonstrated selective dissent during the voting process. While institutions voted unanimously for the financial statements and dividend, they cast 3,543,780 votes against the reappointment of Dr. Sunny Sharma. This represented 5.94% of the votes polled by the institutional category, contrasting sharply with the near-unanimous support from promoters and non-institutional public shareholders.

Marksans Pharma reported a consolidated net profit of ₹1,594.07 million for the quarter ended June 30, 2026, a 174% increase from ₹582.02 million in the corresponding quarter of the previous year. This sharp rise in profitability underscores strong operational performance and favorable foreign exchange impacts during the period. Consolidated revenue from operations reached ₹8,407.96 million, up 36% year-on-year from ₹6,199.89 million, driven by growth across its global pharmaceutical segments. The Board of Directors approved these unaudited financial results at a meeting held on August 12, 2026.

The statutory auditors, M/s. MSKA & Associates LLP, submitted limited review reports for both standalone and consolidated financial results with an unmodified opinion, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were prepared in accordance with Indian Accounting Standard 34 'Interim Financial Reporting'.

Financial Performance

The company’s total income rose to ₹8,662.00 million from ₹6,256.30 million in Q1FY25. Total expenses increased to ₹6,596.29 million from ₹5,490.32 million, primarily due to higher cost of materials consumed (₹2,206.69 million vs ₹1,926.94 million) and employee benefits expense (₹1,142.94 million vs ₹983.85 million). Profit before tax climbed to ₹2,065.71 million from ₹765.98 million. Total tax expense was ₹471.64 million, compared to ₹183.96 million in the prior year quarter.

Standalone net profit was ₹690.37 million, down from ₹919.23 million in Q4FY26 but significantly higher than the ₹480.56 million reported in Q1FY25. Standalone revenue declined to ₹3,211.87 million from ₹3,615.73 million in the preceding quarter.

Strategic Acquisitions and Other Developments

During the quarter, Marksans Pharma acquired 100% of the share capital of QliniQ B.V., a Netherlands-based healthcare solutions provider, for a consideration of EUR 7.50 Million. QliniQ B.V. became a wholly owned subsidiary effective April 1, 2026. Subsequent to the quarter-end, the company completed the acquisition of ABCnow GmbH, a Germany-based pharmaceutical firm with frontend sales and distribution capabilities, for EUR 1.10 Million.

Additionally, the company granted 300,000 stock options under the Marksans Employees Stock Option Scheme 2024 to eligible employees. Each option is exercisable into one equity share with a face value of ₹1.

What the Numbers Show

A significant portion of the income growth stems from other income, which includes a net gain on foreign exchange differences of ₹120.01 million in the consolidated results. This compares to a net loss of ₹38.93 million in Q1FY25, indicating that currency fluctuations contributed materially to the bottom-line improvement. While operational revenues grew robustly, the reversal in forex losses highlights the sensitivity of the company's international operations to currency movements.